Redeye has revisited Orexo's valuation with an in-depth company study and a re-think of the company’s pipeline potential, especially the digital therapies. We recalculate Orexo’s fair value per share at SEK 80, while we also look at qualitative factors such as culture, innovation and leadership, which while difficult to put into an excel model, are important for sustainable value creation, we argue.